Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 623

Results For "PAT"

7225 News Found

cbdMD becomes first American CBD brand to receive UK validation
Biotech | February 19, 2022

cbdMD becomes first American CBD brand to receive UK validation

The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK


Amneal expands injectables portfolio with four new products
Drug Approval | February 19, 2022

Amneal expands injectables portfolio with four new products

Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market


Piramal Pharma appoints Amyra Dastur as brand ambassador for lacto calamine range
News | February 19, 2022

Piramal Pharma appoints Amyra Dastur as brand ambassador for lacto calamine range

The brand has added a range of exciting new products especially formulated for oily skin.


Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
News | February 19, 2022

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study


Indian pharma industry needs a winning partnership
News | February 19, 2022

Indian pharma industry needs a winning partnership

The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines


Covid-19 fuels innovative PCR-based detection methods
Medical Device | February 19, 2022

Covid-19 fuels innovative PCR-based detection methods

According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years


Arrowhead Pharmaceuticals initiates study of ARO-C3
News | February 19, 2022

Arrowhead Pharmaceuticals initiates study of ARO-C3

AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3


Abbott recalls powder formula manufactured at Sturgis, Mich., plant
News | February 19, 2022

Abbott recalls powder formula manufactured at Sturgis, Mich., plant

Recall does not include any metabolic deficiency nutrition formulas


USFDA clears Kairos Pharma’s IND to treat prostrate cancer
Biotech | February 18, 2022

USFDA clears Kairos Pharma’s IND to treat prostrate cancer

Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope


ValGenesis selected for validating French pharma firm
Digitisation | February 18, 2022

ValGenesis selected for validating French pharma firm

With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time